Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery
- PMID: 23778558
- DOI: 10.1007/s00259-013-2471-2
Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery
Abstract
Purpose: Molecular optical imaging using monoclonal antibodies is slow with low tumour to background ratio. We used anti-HER2 VHHs conjugated to IRDye 800CW to investigate their potential as probes for rapid optical molecular imaging of HER2-positive tumours by the determination of tumour accumulation and tumour to background levels.
Methods: Three anti-HER2 VHHs (11A4, 18C3, 22G12) were selected with phage display and produced in Escherichia coli. Binding affinities of these probes to SKBR3 cells were determined before and after site-specific conjugation to IRDye 800CW. To determine the potential of VHH-IR as imaging probes, serial optical imaging studies were carried out using human SKBR3 and human MDA-MB-231 xenograft breast cancer models. Performance of the anti-HER2 VHH-IR was compared to that of trastuzumab-IR and a non-HER2-specific VHH-IR. Image-guided surgery was performed during which SKBR3 tumour was removed under the guidance of the VHH-IR signal.
Results: Site-specific conjugation of IRDye 800CW to three anti-HER2 VHHs preserved high affinity binding with the following dissociation constants (KD): 11A4 1.9 ± 0.03, 18C3 14.3 ± 1.8 and 22G12 3.2 ± 0.5 nM. Based upon different criteria such as binding, production yield and tumour accumulation, 11A4 was selected for further studies. Comparison of 11A4-IR with trastuzumab-IR showed ∼20 times faster tumour accumulation of the anti-HER2 VHH, with a much higher contrast between tumour and background tissue (11A4-IR 2.5 ± 0.3, trastuzumab-IR 1.4 ± 0.4, 4 h post-injection). 11A4-IR was demonstrated to be a useful tool in image-guided surgery.
Conclusion: VHH-IR led to a much faster tumour accumulation with high tumour to background ratios as compared to trastuzumab-IR allowing same-day imaging for clinical investigation as well as image-guided surgery.
Similar articles
-
Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.J Nucl Med. 2007 Sep;48(9):1501-10. doi: 10.2967/jnumed.107.042234. J Nucl Med. 2007. PMID: 17785729
-
Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.Theranostics. 2021 Mar 13;11(11):5525-5538. doi: 10.7150/thno.57510. eCollection 2021. Theranostics. 2021. PMID: 33859761 Free PMC article.
-
Optical imaging of pre-invasive breast cancer with a combination of VHHs targeting CAIX and HER2 increases contrast and facilitates tumour characterization.EJNMMI Res. 2016 Dec;6(1):14. doi: 10.1186/s13550-016-0166-y. Epub 2016 Feb 10. EJNMMI Res. 2016. PMID: 26860296 Free PMC article.
-
111In-(Diethylenetriamine pentaacetic acid)n-trastuzumab-(IRDye 800CW)m.2009 Jan 5 [updated 2009 Apr 5]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2009 Jan 5 [updated 2009 Apr 5]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641695 Free Books & Documents. Review.
-
Applications of Nanobodies in Biological Imaging.Cancer Biother Radiopharm. 2025 Aug;40(6):365-376. doi: 10.1089/cbr.2025.0005. Epub 2025 Apr 24. Cancer Biother Radiopharm. 2025. PMID: 40274307 Review.
Cited by
-
CDH17 nanobodies facilitate rapid imaging of gastric cancer and efficient delivery of immunotoxin.Biomater Res. 2022 Nov 26;26(1):64. doi: 10.1186/s40824-022-00312-3. Biomater Res. 2022. PMID: 36435809 Free PMC article.
-
A small protein probe for correlated microscopy of endogenous proteins.Histochem Cell Biol. 2018 Mar;149(3):261-268. doi: 10.1007/s00418-018-1632-6. Epub 2018 Jan 11. Histochem Cell Biol. 2018. PMID: 29327239 Free PMC article.
-
Nanobodies: Robust miniprotein binders in biomedicine.Adv Drug Deliv Rev. 2023 Apr;195:114726. doi: 10.1016/j.addr.2023.114726. Epub 2023 Feb 7. Adv Drug Deliv Rev. 2023. PMID: 36754285 Free PMC article. Review.
-
Dual Targeting of Endothelial and Cancer Cells Potentiates In Vitro Nanobody-Targeted Photodynamic Therapy.Cancers (Basel). 2020 Sep 23;12(10):2732. doi: 10.3390/cancers12102732. Cancers (Basel). 2020. PMID: 32977602 Free PMC article.
-
VHH-Photosensitizer Conjugates for Targeted Photodynamic Therapy of Met-Overexpressing Tumor Cells.Antibodies (Basel). 2019 Apr 4;8(2):26. doi: 10.3390/antib8020026. Antibodies (Basel). 2019. PMID: 31544832 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous